NurExone Biologic Inc. has received first place in the Healthcare category at the BOLD Awards VII Gala, held March 27, 2026, in Barcelona. The award recognizes the company's leadership in developing exosome-based therapies for central nervous system injuries. This accolade follows the company's selection by a panel of global industry leaders, underscoring its position in the regenerative medicine field. The BOLD Awards recognition comes at a significant time for the biotechnology sector, where innovative treatments for central nervous system injuries represent a substantial unmet medical need.
The company's lead product, ExoPTEN, has demonstrated strong preclinical data supporting its clinical potential for treating acute spinal cord and optic nerve injuries. Regulatory progress, including obtaining Orphan Drug Designation, facilitates the roadmap toward clinical trials in the United States and Europe. The company is also expected to offer exosome solutions and targeted delivery systems for other indications through its commercial strategy. The company's focus on minimally invasive targeted delivery systems could potentially transform treatment paradigms for patients with spinal cord and optic nerve damage.
Concurrently, NurExone reported plans to engage Investor Brand Network (IBN) to support investor awareness efforts, subject to TSX Venture Exchange approval. The engagement is scheduled to begin April 1, 2026, and includes distribution of news and updates across more than 5,000 outlets. The one-year agreement carries a monthly fee of $6,500 and aims to strengthen market visibility and long-term shareholder value. The strategic partnership with IBN is designed to communicate these developments to a broader investment community as the company advances toward clinical milestones.
NurExone has established Exo-Top, a U.S. subsidiary, to anchor its North American activity and growth strategy. The company is listed on the TSX Venture Exchange under the symbol NRX, on the OTCQB under NRXBF, and on the Frankfurt Stock Exchange under J90. For more information about the company, visit https://nurexone.com/.
